Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



Curran Terrie Create: Alert

All | News | Filings
Date FiledTypeDescription
07/17/2023 4 Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 200,000 shares @ $0
Disposed/sold 175,000 options @ $32.2, valued at $5.6M
Disposed/sold 225,000 options @ $39.11, valued at $8.8M
06/02/2023 4 Curran Terrie (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns: Granted 4,375 shares @ $0
Granted 12,220 options to buy @ $7.51, valued at $91.8k
03/10/2023 4 Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 3,673 shares @ $0
Disposed/sold 33,846 options to buy @ $11.3, valued at $382.5k
Disposed/sold 11,154 options to buy @ $12.68, valued at $141.4k
Disposed/sold 22,500 options to buy @ $13.14, valued at $295.7k
Disposed/sold 22,500 options to buy @ $24.25, valued at $545.6k
Disposed/sold 5,250 options to buy @ $7.65, valued at $40.2k
Disposed/sold 21,603 options to buy @ $21.47, valued at $463.8k
Disposed/sold 21,096 options to buy @ $22.71, valued at $479.1k
01/20/2023 4 Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 97,500 shares @ $0
Sold 5,821 shares @ $8.1995, valued at $47.7k
Granted 162,500 options to buy @ $8.35, valued at $1.4M
11/23/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/28/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/02/2022 4 Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 7,500 shares @ $0
06/03/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/20/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/21/2022 4 Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 41,250 shares @ $0
Granted 206,250 options to buy @ $15.21, valued at $3.1M
11/09/2021 4 Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Granted 21,096 options to buy @ $22.71, valued at $479.1k
09/13/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/03/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/11/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/23/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/29/2021 4 Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.
Txns: Granted 225,000 options to buy @ $39.11, valued at $8.8M
11/04/2020 4 Curran Terrie (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns: Granted 37,500 options to buy @ $18.72, valued at $702k
09/17/2020 4 Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Granted 21,603 options to buy @ $21.47, valued at $463.8k
07/02/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/22/2019 4 Curran Terrie (PRES., GLBL INFLAM. AND IMMUN.) has filed a Form 4 on CELGENE CORP /DE/
Txns: Disposed/sold 3,426 restricted stock units @ $0
Disposed/sold 1,857 restricted stock units @ $0
Disposed/sold 6,593 restricted stock units @ $0
Disposed/sold 4,120 restricted stock units @ $0
Disposed/sold 27,749 restricted stock units @ $0
11/22/2019 4 Curran Terrie (PRES., GLBL INFLAM. AND IMMUN.) has filed a Form 4 on CELGENE CORP /DE/
Txns: Granted 5,139 shares @ $0
Granted 9,889 shares @ $0
Granted 17,840 shares @ $0
Disposed/sold 37,181 shares @ $0
Disposed/sold 327 shares @ $0
Disposed/sold 5,500 options to buy @ $58.33, valued at $320.8k
Disposed/sold 3,750 options to buy @ $81.56, valued at $305.9k
Disposed/sold 7,500 options to buy @ $87.64, valued at $657.3k
Disposed/sold 5,000 options to buy @ $103.1, valued at $515.5k
Disposed/sold 7,050 options to buy @ $117.18, valued at $826.1k
Disposed/sold 5,000 options to buy @ $118.57, valued at $592.9k
09/19/2019 4 Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/
Txns: Sold 4,500 shares @ $98.2, valued at $441.9k
Sold 6,838 shares @ $98.31, valued at $672.2k
Exercised 4,500 options to buy @ $58.33, valued at $262.5k
08/27/2019 4 Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Granted 58,608 options to buy @ $7.65, valued at $448.4k
05/06/2019 4 Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/
Txns: Paid exercise price by delivering 490 shares @ $95.21, valued at $46.7k
Exercised 1,563 restricted stock units @ $0
03/05/2019 4 Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/
Txns: Granted 27,749 restricted stock units @ $0
02/06/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/18/2018 4 Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/
Txns: Paid exercise price by delivering 1,231 shares @ $68.2, valued at $84k
Exercised 2,500 restricted stock units @ $0
10/31/2018 4 Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/
Txns: Granted 12,983 options to buy @ $71.43, valued at $927.4k
09/04/2018 4 Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Granted 22,500 options to buy @ $24.25, valued at $545.6k
05/17/2018 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/08/2018 4 Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/
Txns: Paid exercise price by delivering 856 shares @ $86.89, valued at $74.4k
Exercised 2,500 restricted stock units @ $0
01/31/2018 4 Curran Terrie (See remarks) has filed a Form 4 on CELGENE CORP /DE/
Txns: Granted 6,777 options to buy @ $103.26, valued at $699.8k
12/20/2017 4 Curran Terrie (See remarks) has filed a Form 4 on CELGENE CORP /DE/
Txns: Paid exercise price by delivering 683 shares @ $107.06, valued at $73.1k
Exercised 1,765 restricted stock units @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy